Magnesium Sulfate Dosing
For eclampsia prevention/treatment in preeclampsia, use a 4-5 g IV loading dose over 15-30 minutes, followed by 1-2 g/hour continuous infusion until 24 hours postpartum. For drug-induced torsades de pointes, administer 2 g IV as a first-line agent, repeating as needed if episodes persist.
Preeclampsia and Eclampsia
The FDA-approved and guideline-endorsed regimen consists of 1:
Loading dose:
- 4-5 g IV in 250 mL D5W or normal saline, infused over 15-30 minutes
- Alternative: 4 g IV plus 10 g IM (5 g in each buttock) simultaneously
Maintenance dose:
- 1-2 g/hour continuous IV infusion
- Alternative: 4-5 g IM into alternate buttocks every 4 hours
Duration:
- Continue until delivery and for 24 hours postpartum 2
- One Latin American study suggested stopping after 8 g total pre-delivery dose, but ISSHP guidelines recommend continuing the full 24-hour postpartum course given known postpartum eclampsia risk 2
Target serum level: 4.8-6 mg/dL (4-6 mg/100 mL) for seizure control 3, 1
Critical Monitoring Requirements
Before each dose, verify:
- Patellar reflexes present
- Respiratory rate ≥12-16/minute
- Urine output ≥25-30 mL/hour (or ≥100 mL over 4 hours)
Maximum daily dose: 30-40 g over 24 hours 1
Special Populations
Obese women (BMI ≥35): Standard Zuspan dosing (4 g load, 1 g/hour) results in 100% subtherapeutic levels at 4 hours. Consider higher dosing: 6 g IV load followed by 2 g/hour maintenance, which achieves therapeutic levels in 63% of patients 4. This represents emerging evidence that may warrant protocol modification in this population.
Renal insufficiency: Maximum 20 g over 48 hours with frequent serum magnesium monitoring 1
Low-resource settings (Pritchard regimen):
- Loading: 4 g IV + 10 g IM (5 g each buttock)
- Maintenance: 5 g IM every 4 hours in alternate buttocks 2
Torsades de Pointes
For drug-induced TdP with prolonged QT: 2 g IV infusion as first-line therapy, regardless of serum magnesium level 3. Repeat 2 g doses if episodes persist. This applies specifically to patients taking QT-prolonging drugs who present with TdP and QTc >500 ms or increase ≥60 ms from baseline.
Fetal Neuroprotection
For imminent preterm birth ≤33+6 weeks: Use the same dosing regimens validated in the MAGPIE and Eclampsia trials 2. The 2018 ISSHP guidelines explicitly state "the dosing regimens used in the Eclampsia and MAGPIE trials should be used" without specifying alternative doses for this indication.
Indications:
- Active labor with cervical dilation ≥4 cm
- Preterm prelabor rupture of membranes with imminent delivery
- Planned preterm birth for maternal/fetal indications
Continue until delivery and for 24 hours postpartum 5.
Common Pitfalls
Do not exceed 150 mg/minute IV push rate (1.5 mL of 10% solution) except in severe eclampsia with active seizures 1. Rapid administration increases toxicity risk.
Avoid continuous use beyond 5-7 days in pregnancy as this causes fetal abnormalities 1.
Monitor for toxicity: Loss of patellar reflexes occurs at 8-12 mg/dL, respiratory depression at 12-15 mg/dL, cardiac arrest at >25 mg/dL. Keep calcium gluconate 1 g (10 mL of 10% solution) at bedside as antidote.
Drug interactions: Magnesium potentiates neuromuscular blockade and may reduce antibiotic activity of aminoglycosides and tetracyclines 1.
Fluid restriction: Limit total IV fluids to 60-80 mL/hour in preeclamptic women to prevent pulmonary edema 2.
Alternative Indications (Non-Obstetric)
- Hypomagnesemia (mild): 1 g IM every 6 hours × 4 doses
- Hypomagnesemia (severe): 5 g in 1 L fluid over 3 hours IV
- Acute asthma (adults): 1.2-2 g IV over 15-30 minutes reduces hospital admissions by 7% (NNT ~14) 6
- Seizures (non-eclamptic): 1 g IM or IV
The evidence strongly supports standardized protocols within institutions, with the MAGPIE/Eclampsia trial regimens representing the gold standard for obstetric indications 2.